Cl[CH2:2][CH2:3][CH2:4][CH2:5][C:6]([N:8]1[C:14]2[CH:15]=[CH:16][CH:17]=[CH:18][C:13]=2[C:12](=[O:19])[CH2:11][CH2:10][CH2:9]1)=[O:7].[C:20]([C:24]1[N:29]=[C:28]([N:30]2[CH2:35][CH2:34][NH:33][CH2:32][CH2:31]2)[CH:27]=[C:26]([C:36]([F:39])([F:38])[F:37])[N:25]=1)([CH3:23])([CH3:22])[CH3:21].[Na+].[Br-].C(N(C(C)C)CC)(C)C>CN1CCCC1=O>[C:20]([C:24]1[N:29]=[C:28]([N:30]2[CH2:31][CH2:32][N:33]([CH2:2][CH2:3][CH2:4][CH2:5][C:6]([N:8]3[C:14]4[CH:15]=[CH:16][CH:17]=[CH:18][C:13]=4[C:12](=[O:19])[CH2:11][CH2:10][CH2:9]3)=[O:7])[CH2:34][CH2:35]2)[CH:27]=[C:26]([C:36]([F:37])([F:38])[F:39])[N:25]=1)([CH3:23])([CH3:21])[CH3:22]1-(5-Chloropentanoyl)-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one from Example 12a (1.43 mmol, 0.50 g), 2-tert-butyl-4-piperazin-1-yl-6-(trifluoromethyl)pyrimidine (1.43 mmol, 0.41 g, preparation according to DE 19735410), NaBr (7.14 mmol, 0.74 g), DIPEA (diisopropylethylamine) (14.01 mmol, 1.81 g) and N-methylpyrrolidinone (0.6 ml) were heated to 120° C. for 5 h. Subsequently, the reaction mixture was filtered and the resulting filtrate was concentrated to dryness. Afterward, ethyl acetate was added to the resulting residue and it was washed with saturated, aqueous sodium chloride solution. The organic phase was dried and then concentrated to dryness. The residue was purified by chromatography on silica gel, eluent: methyl tert-butyl ether/methanol (0-100%); to obtain 0.31 g of the title compound.